A major challenge for Streptococcus pyogenes vaccine development is the identification of epitopes that confer protection from infection by multiple S. pyogenes M-types. Here we have identified the most common variant sequences in the C-repeat region (CRR) of 77 different M-types, and have incorporated them into three constructs, SV1, SV2 and SV3. Each unique sequence was into the polyvalent constructs in a manner that produced an alpha-helical conformation, a conformational characteristic of the CRR. Antibodies raised against each of these constructs recognise M-proteins that vary in their CRR, and bind to the surface of multiple S. pyogenes isolates. Antibodies raised against one construct, SV1, containing five variant sequences, kill S. pyogenes 88-30 and ES61 in in vitro bactericidal assays. Our findings demonstrate that linkage of multiple variant sequences into a single recombinant construct overcomes the need to embed the variant sequences in foreign helix promoting flanking sequences, and demonstrates the viability of the polyvalent candidates as global S. pyogenes vaccine candidates.
Introduction
Streptococcus pyogenes (group A Streptococcus, GAS) is a human pathogen that colonises the throat or skin, resulting in diseases that vary in presentation and clinical severity. S. pyogenes infection is the leading cause of bacterial pharyngitis, and is also responsible for cellulitis, kidney disease (post-streptococcal glomerulonephritis (PSGN), rheumatic fever (RF) and rheumatic heart disease (RHD)). Further S. pyogenes is also the causative agent of severe invasive diseases including necrotising fasciitis and toxic shock syndrome (1)1. S. pyogenes associated diseases are estimated to kill half a million people each year (2)2. The majority of these deaths are attributable to RHD, and mainly occur in developing nations. As RF and RHD are an autoimmune sequelae of S.
pyogenes infection in which immune molecules and cells raised against epitopes of bacterial proteins attack host protein and tissues (3)3, antibiotic treatment is not a viable option for the treatment primary episodes of RF/RHD. A preventive vaccine is therefore the ideal approach for prevention of RF/RHD and other S. pyogenes associated diseases.
The M-protein, the major virulence factor of S. pyogenes is the favoured target of vaccine development (4)5. The major function of the M-protein is the prevention of opsonophagocytosis (1)6. Reinforcing the importance of this protein to the virulence of S. pyogenes, variants of the Mprotein may also possess additional biological properties (7) . Structurally, the protein forms a coiled-coil dimer that extends from the bacterial surface to beyond the peptidoglycan layer 8 (9) .
The hypervariable amino-terminus is followed by A, B and C-repeat regions that increase in amino acid conservation between variant M-proteins. Diversity in the hypervariable region is also used to categorise S. pyogenes into M-types based on discriminatory serological responses to this region, or emm-types, based on nucleotide sequence variation in the corresponding region of the emm gene (9)9. To date more than 150 emm-types have been described. S. pyogenes expressing M1, M5 and M6 are classically associated RHD, M49 and M57 with PSGN, and M1, M3 and M18 with severe invasive disease (1)1. Associations between M-type and disease are not as strong in many populations where streptococcal infection is endemic.
Rather, large numbers of M-types circulate (14) 15, none of which dominates disease associations.
The presence of epitopes within the central region of the M-protein responsible for immunologically cross-reactive immune responses which could contribute to RHD (15)15 preclude the use of full length M-proteins as a vaccine candidates. While the hyper-variable amino-terminal region induces antibodies that are bactericidal, these antibodies are also M-type specific, and only effective in killing homologues of S. pyogenes isolates. Nevertheless, the utility of incorporating multiple N-terminal epitopes from multiple M-proteins into a single formulation has been evaluated.
An alternative approach is to target the less immunogenic, but more conserved C-repeat region (CRR) of the M-protein, which may provide protection against multiple M-types. Epitope mapping of the CRR has previously identified a short amino acid sequence, that when flanked by yeast GCN4 sequences maintains the helicity of the peptide and when conjugated to Diphtheria Toxoid (DT) or other carrier molecules, induces murine antibody responses that kill S. pyogenes in in vitro assays and protect mice from intraperitoneal and intranasal challenge This full chimeric 29mer peptide is called J14 i.
The J14 i target sequence within the CRR is only found in the third CRR block (CRRB3) of Class II M-proteins, the CRRB closest to the bacterial surface. A variant sequence (J14 i .1) is present in Class I M-proteins (27)27. Variants of J14 i are found in CRRB1 and CRRB2, which are further from the bacterial surface. While it is well recognized that a single CRRB is sufficient for the biological role of M protein (33)33, it is not clear whether antibodies to the CRRB3 are adequate to protect against infection with S. pyogenes strains in all biological conditions. For instance, highly mucoid strains may not be able to project the surface proximal CRRB sufficiently far enough beyond the capsule for recognition by antibody. Furthermore, vaccine pressures may select for replacement of this CRRB by other variants that do not react with J14 antibodies.
Here we have evaluated a panel of polyvalent recombinant vaccine constructs incorporating common J14 i -variants found in CRRB1, CRRB2 and CRRB3 from multiple M-types. By linking the variants in a manner that maintains heptad periodicity across the entire protein, we have eliminated the need for heterologous GCN4 sequence. Antibodies raised against these novel constructs bind to a wide range of M-proteins, and the surface of heterologous S. pyogenes strains.
Further we also show that antibodies raised against SV1, a construct containing five J14 i -variant sequences kill S. pyogenes in in vitro bactericidal assays.
Methods
Bacterial strains. S. pyogenes isolates used in the study are listed in Table 1 . These strains were selected as they express M-proteins that possess different CRRs. S. pyogenes 2031 is an M1 reference isolate. S. pyogenes 88-30 and ES61 are clinical isolates that possess the emm97 and emm92 genes. Unless otherwise specified S. pyogenes were grown in Todd Hewitt Broth (THB), and on Todd Hewitt agar supplemented with 2% horse blood (THA).
Peptide synthesis and protein expression. Peptides used in this study are listed in Table 2 . All peptides were synthesised using Fmoc chemistry, and purified to greater than 90% using HPLC prior to use in ELISA. The J14-variants contain J14 i -variant amino acid sequence flanked by GCN4 amino acid sequence. p145 peptides contain J14 i -variant sequence and an additional six amino sequences native to the M-protein. Reverse translation of the amino acid sequence of SV1, SV2 and SV3, taking into account codon bias in Escherichia coli, was used to design nucleic acid sequences encoding each of these vaccine candidates. These nucleotide sequences were synthesised by DNA2.0 (USA), cloned into the expression vector pET41 (Novagen, Inc), and subsequently transformed into E. coli C43 (Lucigen Corp). All recombinant proteins were expressed by the addition of 1mM IPTG to growth media, and purified through nickel affinity chromatography.
Structural characterisation of proteins. The secondary structure of proteins and peptides was assessed by Circular Dichroism (CD) spectroscopy (37)37. Samples (final concentration ca 0.03 mg/ml) were dissolved in 10 mM sodium phosphate buffer (pH 7.0) with 20 mM NaCl and varying concentrations of 2,2,2-trifluoroethanol (TFE). Spectra were acquired from 190 to 260 nm as the average of 3 repeats at 20°C with a spectral bandwidth of 1 nm and a scanning speed of 10 nm/min using a JASCO J-715 CD spectrometer equipped with a Peltier temperature control. Acquired data were corrected for buffer baseline, normalised to reported mean residue ellipticity [Θ] and smoothed using the program ACDP. The secondary structure content for each sample was subsequently predicted with spectrum deconvolution using a linear combination of three Fasman prototype spectra (α-helix, β-strand and random coil) as implemented in the program ACDP (38)38.
The stability of samples at varying pH values was assessed by dissolving the peptide in 20 mM NaCl, 10% TFE and 10 mM pH buffer; sodium acetate was used to buffer at pH 4 and pH 9, sodium phosphate from pH 5 to 8, and glycine at pH 10. Samples were prepared 2 hrs before measurement and assessed at 20°C. To investigate the thermal stability, samples were dissolved in 20 mM NaCl, 10% TFE and 10 mM sodium phosphate (pH 7.0), and the CD at 222 nm was monitored while changing the temperature at a rate of 1 K min -1 . The temperature was increased from 20°C to 80°C and then immediately decreased at the same rate to 20°C. Full spectra were acquired as described above before starting the heating ramp (20°C), at 80°C, and again after the cooling ramp (20°C).
Immunisation. Prior to immunisation, J14 was conjugated to Diphtheria Toxoid (DT) through a Cterminal cysteine using 6'-maleimido-caproyl n-hydroxy succinimide (MCS). Recombinant ELISA. ELISAs were performed as previously described Ninety-six well ELISA plates were coated with peptide or protein (5.0 µg/ml) dissolved in carbonate coating buffer and blocked with 5% skim milk/PBS/Tween20. Primary sera were diluted 1:2 down the plates, which were then incubated at 37ºC for 90 min. The plates were washed in PBS-Tween, and secondary goat anti-mouse IgG conjugated to Horse Radish Peroxidase added.
After a further 90 min incubation, the plates were washed, incubated with SigmaFAST OPD tablets (Sigma, USA) and absorbance (450 nm ) measured using a Benchmark (BioRad, USA) microplate reader. The antibody titre endpoint was determined as the lowest dilution in which the absorbance was three standard deviations higher than absorbance observed in sera from PBS immunised mice.
Titres for each group are expressed as the arithmetic mean ± standard error. Statistical comparisons between groups were performed using the Kruskal-Wallis test with Dunns post-test used to compare individual groups.
To compare binding of J14-DT sera to the J14 i -variant sequences, sera diluted 1:1,000 was added to the wells of ELISA plates containing p145-variant peptides, and ELISA completed as described above. The mean absorbance associated with each peptide was determined after subtraction of mean absorbance measured for PBS-control sera. Competition ELISAs were also performed to assess the relative affinity of J14 antisera to peptides containing J14 i -variants. For these experiments ELISA plates were blocked with 5% skim milk/PBS Tween as described above. One hundred microlitres of antisera diluted 1:10,000 was then added to all wells of the plate. Free peptide (10µg.ml -1 ) was added to the first row, and subsequently diluted 1:2 down the plate to a final concentration of 0.02µg.ml -1 . After incubation for 30 minutes, the peptide/antibody mixtures were transferred to the wells of a second set of ELISA plates that had been pre-coated with J14. The competition ELISA was then completed as per the standard protocol and percent inhibition calculated by comparing the optical density of wells containing antisera pre-incubated with peptide to wells on the same plate containing antisera that had been incubated in the absence of peptide. A non-specific peptide and normal mouse sera were used as controls in these experiments.
Immunofluorescence microscopy and FACS. Immunofluorescence microscopy (IFA) and FACS were used to qualitatively assess binding of antibodies to the surface of S. pyogenes (39)39. For IFA S. pyogenes was grown overnight, fixed to a polylysine slide (Biolabs Scientific, New Zealand)
with 3% paraformaldehyde and blocked with 5% skim milk/PBS/-Tween. To prevent non-specific Fc-IgG binding by streptococcal surface proteins, slides were also blocked with non-specific human polyclonal IgG (AbD Serotec, UK). After the secondary blocking step, the slides were incubated with appropriately diluted antisera, washed, and incubated with secondary goat anti-mouse-IgG-FITC labelled antibody (Invitrogen, USA) diluted 1:200 in 0.5% skim milk/PBS/Tween.
VectaShield (Vector Laboratories Inc, USA) and a coverslip was added to each sample, and slides viewed under a Leica Confocal microscope at a wavelength of 500-650nm.
FACS was also employed to investigate the binding of antisera to the surface of logarithmically growing S. pyogenes. Bacteria were first grown to mid-log phase, harvested, and washed in PBS.
Non-specific binding of antibodies to the surface of the bacteria was inhibited by incubations with To examine the affinity of J14 antisera for J14 i -variant sequences, a panel of twelve p145-like peptides were used in ELISA with J14-DT antisera diluted 1:1,000 ( Figure 1) . When compared to mean absorbance observed using J14, the mean absorbance for all p145-variant peptides, including p145, was significantly lower. In turn, the mean absorbance observed with p145 was at least twofold higher than that observed with other p145-variants. While J14-DT antisera bound to p145, p145.2, p145.3 and p145.5, the absorbance observed with another eight peptides was negligibly higher than negative control PBS sera.
As the attachment of the p145-variant peptides to ELISA plates may occur with different efficiencies, or alter the conformation of peptides and reduced recognition by J14 antibodies, competition ELISA using free p145 variants and bound J14 were next conducted. As expected the pre-incubation of antisera with increasing concentrations of free J14 resulted in a reduction in binding bound J14, with fifty percent inhibition occurring at 0.1 μg.ml To examine the immunogenicity of vaccine constructs, B10.Br mice were subcutaneously immunised with the four recombinant proteins and J14-DT. All the antigens were immunogenic, with mean titres against the immunising antigen ranging from 153,600 ± 21,000 for the SV1 group to 1,280,000 ± 174900 for the J14-DT immunised group (Figure 4 ). When ELISA were conducted against J14, the mean titres observed for the J14-DT ad SV2 (40,000 ± 17,000) groups were at least ten-fold higher than mean titres observed for SV1 and SV3 groups. As the true target of antibodies raised against the vaccine candidates is the M-protein, we next conducted ELISA against the M1 protein, an M-protein possessing two J14.2 i repeat sequences, and J14. In this instance the greatest anti-M1 titres were observed with the SV1 group (273,100 ± 34,000), and lowest titres observed for the J14-DT group (141,100 ± 37,300). However there was no statistical difference between the mean titres of any group. ELISAs and Western blot performed against two other Mproteins (M65 and M124) using pooled antisera also demonstrated the affinity of SV1, SV2 and SV3 antibodies for heterologous M-proteins was as great as that of J14-DT antisera (data not shown). Isotyping profiles of sera raised all the antigen including J14-DT, were also similar pyogenes M1, ES61 and 88-30 with relatively equal intensity ( Figure 6 ). However, the fluorescence observed with SV2-antisera was weaker observed with other sera. No fluorescence was observed using PBS control sera. When assessed by FACS using log-phase bacteria only SV1 and SV3
antibodies were shown to bind all three S. pyogenes at levels statistically greater PBS sera. J14-DT sera bound to S. pyogenes ES61 and 88-30 in FACS, but not M1. SV2 antibodies only bound to
S. pyogenes 88-30.
Antibodies raised against SV1 are bactericidal. To examine the functionality of antibodies raised against each of the recombinant vaccine antigens in vitro bactericidal assays with S. pyogenes 88-30
and S. pyogenes ES61. In these assays heat inactivated immune and control sera were incubated with S. pyogenes and human blood that was pre-screened to confirm the absence of natural antistreptococcal antibodies. All experiments were performed independently in triplicate and results presented as the reduction in CFU recovered when compared to incubation of bacteria with PBS immune sera (Table 5) . In these experiments, only antibodies raised against SV1 were bactericidal towards both S. pyogenes 88-30 and ES61. The mean percent reduction in recovery of S. pyogenes 88-30 was 27 ± 14%, 28 ± 28% and 38 ± 17% for SV1, SV2 and SV3 groups respectively. The mean percent reduction in CFU for the three experiments using S. pyogenes ES61 ranged from 46.4 to 99.1%.
Structural properties of vaccine candidates.
Maintenance of the helical structure of amino acid sequence within J14 i , matching the conformation of the M-protein is considered to be an important factor in the efficacy of vaccines from the conserved region of the M-protein
The propensity for recombinant vaccine antigens and J14 to form alpha-helical secondary structure was therefore assessed using CD spectroscopy (Figure 7 ). After deconvolution, SV3 was the only construct with greater than 50% alpha-helical structure in aqueous solution. When the spectra were examined in increasing concentrations of TFE, all proteins were predicted to assume alpha-helical structure at 10% TFE, irrespective of the presence of GCN4 flanking regions. In contrast, only 50%
of J14 was predicted to form alpha-helical structure in 40% TFE.
As antibodies raised against SV1 were the only ones to kill both strains or S. pyogenes, the stability of the secondary structure of this construct was further analysed with respect to temperature and pH pyogenes vaccine design.
Previously we reported that fusion of J14 with the H12 domain of SfbI, another S. pyogenes surface protein that has been proposed as a S. pyogenes vaccine candidate, resulted in loss of the alphahelical secondary structure. By incorporating a flexible spacer sequence, and incorporating two J14 sequences in tandem, the alpha-helical J14 structure could be restored. In this study all polyvalent constructs were designed to ensure that both heptad periodicity required for coiled coil structure as observed in the parental M-protein, and alpha helicity were maintained along the full length of the proteins. The secondary conformation of all proteins, including those without GCN4 flanking sequences, was subsequently confirmed through circular dichroism. In comparison to J14 and SV2, SV1 and SV3, lack GCN4 amino acid sequence. A greater proportion of the latter's amino acid sequences therefore correspond to M-protein amino acid sequence. Our finding that while J14 and SV2 induced much greater anti-J14 titres, whole M-protein titres were similar for all groups, even in the absence of carrier molecule, suggest that a significant proportion of J14-DT and SV2
antibodies are directed against GCN4 sequence or epitopes that span the GCN4-J14 i junction. The similar M-protein titres observed for all groups also demonstrate that a carrier molecule such as diphtheria toxoid is not required for induction of significant immune responses by SV1, SV2 and SV3 in murine models. Together our data demonstrate that the rationale design of a vaccine undertaken here has resulted in constructs that do not require non-M protein flanking sequence for conformational integrity, or carrier molecule for the induction of significant immune responses.
IFA and FACS both demonstrated that vaccine sera recognised M-protein on the surface of S.
pyogenes. However the binding of sera to the surface of S. pyogenes strains in IFA experiments was qualitatively different to the binding observed in the FACs experiments. IFA was conducted on S.
pyogenes in stationary phase growth, whereas the FACS was conducted on bacteria in log-phase growth. S. pyogenes in logarithmic growth phase are considered to have more capsule on their surface that bacteria in stationary phase. Thus the CRR is may be more accessible to immune molecules in stationary phase than in logarithmic growth. The failure SV3 and J14-DT antibodies to bind to M1 GAS when grown to log-phase would suggest this to be the case for this isolate.
However the ability for all antibodies to bind to 88-30, irrespective of growth phase, may also suggest that the total amount of capsule present on the surface differs between isolates, and may impact antibody binding capacity.
SV1 is a promising GAS vaccine candidate. SV1 possesses the five most common J14 i -variants, and is the only candidate to include J14 i -variants from CRRB1. In all 101 M-type/J14 i -variant combinations examined in the current study, 71% possess two or three of the variant epitopes present in SV1 in their CRRBs. Another 21% possess two copies of J14.1 i , but only contain 2
CRRBs in their full length sequence, demonstrating the advantage that inclusion of multiple sequences has in providing greater strain coverage. Antibodies raised against SV1 recognise purified M-proteins, and bind to the surface of all three S. pyogenes isolates when grown to stationary or log-phase. Importantly SV1 antisera kills S. pyogenes in in vitro assays. As changes in the alpha-helical structure may also result in changes to immune responses, it is also important that SV1 maintains correct conformation in any vaccine formulation. We found the conformation of SV1 to be maintained across a range of pHs. Whilst changes in conformation were observed at higher temperatures, SV1 returned to its native conformation upon cooling suggesting the recombinant protein is also thermodynamically stable. 
